Connect with us

Media OutReach

SL Aesthetic Group Marks 22 Years of Innovation and Regional Expansion in Singapore and Southeast Asia

Published

on

SINGAPORE – Media OutReach Newswire – 15 January 2026 – SL Aesthetic Group celebrates its 22nd anniversary, marking its growth from a single clinic into a multi-brand medical aesthetics and healthcare group.

Founded in Singapore in 2003, the Group has grown to encompass five specialised brands operating more than twenty outlets across Singapore and the region.

  • SL Aesthetic Clinic offers doctor-led skin, face and body treatments, and is one of Singapore’s longest-running medical aesthetics clinic.
  • SkinLab The Medical Spa, a dermatology-focused medical spa, specialises in medical-grade facials and skincare products for sensitive skin.
  • TrichoLab, a dedicated hair and scalp health brand specialising in medical hair loss solutions.
  • Euphie (Malaysia) is the Group’s Malaysia-based extension comprising Euphie Skin Solutions and Euphie Clinic, delivering medically supervised aesthetic care.

The Group has served more than 100,000 patients, with care provided by a team of 12 doctors and more than 100 trained specialists.

Over the past two decades, the concept of beauty and wellness has broadened into a more holistic approach to personal care—one that goes beyond aesthetics to support overall wellbeing. People are placing greater emphasis on long-term health, from their mental health and nutrition to their physical appearance. This shift has driven growing demand for preventive, medically supervised services that integrate aesthetics with broader health concerns.

In response to these changing needs, SL Aesthetic Group has expanded its medical services beyond skin and hair treatments, introducing more than 40 new offerings across its five specialised brand portfolios, including women’s health services.

Dr Kelvin Chua, Founder and Senior Medical Director of SL Aesthetic Group, said: “Reaching 22 years reflects the continuity of care we have built over time. As patient expectations change, our focus remains on delivering medically supervised services that support long-term health and well-being.”

As part of this expansion, the Group launched Prologue The Lifestyle Medical Clinic and Prologue Centre for Women’s Wellness in 2025. Prologue The Lifestyle Medical Clinic focuses on preventive care for chronic conditions, supported by artificial intelligence–enabled health screenings for early detection of conditions such as dementia and cancer. Meanwhile, Prologue Centre for Women’s Wellness addresses women’s health needs across different life stages, including perimenopause, menopause, and postpartum recovery.

Within Singapore, the group strengthened its physical presence with the opening of its tenth SL Aesthetic Clinic and SkinLab The Medical Spa outlet at iMall in Marine Parade, as a response to strong and sustained demand from patients in the eastern region.

Regionally, SL Aesthetic Group marked a milestone as its Malaysia-based brand, Euphie — comprising Euphie Skin Solutions and Euphie Clinic — celebrated its first anniversary. Building on this foundation, the Group plans to open an additional outlet in Malaysia, extending its medically supervised services to a wider patient base.

Looking ahead, SL Aesthetic Group plans to continue expanding its clinical footprint while maintaining regulatory compliance, clinical standards, and patient safety.

For more information, visit: https://slaestheticgroup.com/
Hashtag: #SLAesthetic

The issuer is solely responsible for the content of this announcement.

About SL Aesthetic Group

SL Aesthetic Group is one of Singapore’s longest-established medical aesthetic groups, with a presence in Singapore and Malaysia. The Group houses a diverse portfolio of brands, including SL Aesthetic Clinic, SkinLab The Medical Spa, TrichoLab, PROLOGUE, and Euphie (Malaysia).

Founded in the 2000s, SL Aesthetic Group specialises in skin and hair health, women’s wellness, and holistic medicine. Across its clinics and outlets, the Group offers a comprehensive range of FDA-approved aesthetic and medical treatments, all supervised by trained and certified healthcare professionals holding Certificates of Competency (COC) recognised by the Singapore Medical Council’s Aesthetic Practice Oversight Committee (APOC).

Advertisement

Media OutReach

Zuellig Pharma Acquires Cialis® (Tadalafil) from Lilly in three additional markets in Asia

Published

on

SINGAPORE – Media OutReach Newswire – 12 March 2026 – Zuellig Pharma, a leading healthcare solutions company in Asia, today announced that it has acquired all rights, title, and interest in and to Cialis® (Tadalafil), a leading men’s health product from Eli Lilly and Company (“Lilly”) in Hong Kong, Macau and South Korea.

Following the acquisition, Zuellig Pharma will now own the trademarks, marketing authorizations and license manufacturing know-how for Cialis®, a treatment for erectile dysfunction (ED) and benign prostatic hyperplasia (BPH), in 11 markets in Asia, with the expansion of its ownership into three additional markets beyond the original eight. Zuellig Pharma will also continue to promote and distribute the brand in these markets.

The expanded ownership of Cialis® will widen accessibility of the drug to a significant population of men in Asia who are affected by ED and BPH. The acquisition also aligns with Zuellig Pharma’s strategic priority of building a strong portfolio of owned prescription healthcare products as an integrated healthcare solutions company.

“Our acquisition of Cialis® in three additional markets builds on the strong foundation we established two years ago and highlights our proven success in scaling trusted brands effectively through our commercial capabilities and deep expertise. As we broaden our footprint, we remain focused on delivering sustainable growth and advancing our purpose of making in-demand healthcare solutions more accessible to communities in Asia,” said John Graham, CEO of Zuellig Pharma.
Hashtag: #ZuelligPharma #EliLillyandCompany #Cialis #MensHealth #Healthcare #Pharmaceuticals


The issuer is solely responsible for the content of this announcement.

About Zuellig Pharma

Zuellig Pharma is a leading healthcare solutions company in Asia, and our purpose is to make healthcare more accessible to the communities we serve. We provide world-class distribution, commercialization, and clinical trial support services, underpinned by a strong culture of innovation to support the growing healthcare needs in this region. The company was founded a hundred years ago and has grown to become a multibillion-dollar business covering 18 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world.

Continue Reading

Media OutReach

Ingdan Powers Embodied AI with Humanoid-Style Brain-Cerebellum Chipset to Boost Robotics Ecosystem

Published

on

HONG KONG SAR – Media OutReach Newswire – 12 March 2026 – Ingdan, Inc. (“Ingdan” or the “Company”, stock code: 400.HK; with its subsidiaries (the ”Group”)), a core supplier in the AI computing power supply chain and a leading application technology solutions provider, announces continued progress in strengthening its humanoid robotics ecosystem through an integrated embodied intelligence IC product matrix, supporting the industry’s transition toward large‑scale commercialization.

2026 is widely regarded as a milestone year for humanoid robotics, in which humanoid robots transition from laboratory prototypes and demonstration performances to large‑scale mass production. At CES in January, NVIDIA announced the commercial launch of its physical‑AI core platform Jetson Thor. Tesla is scheduled to officially release the mass‑production engineering version of its Optimus (V3) humanoid robot by the end of March, with plans to initiate million‑unit‑level production lines by the end of 2026—an inflection point widely regarded as the “Model 3 moment” of the humanoid robotics industry. At the same time, Chinese robotics companies such as AGIBOT, Unitree, and Fourier Intelligence have already deployed products at scale in warehousing and logistics scenarios.

Against this backdrop, the upstream hardware focus of the humanoid robotics industry is increasingly converging on “Brain-Cerebellum” collaboration and low‑latency, multi‑joint real‑time control, which are essential to achieving coordinated, smooth, and human‑like robotic motion. During the CMG Spring Festival Gala, robots from multiple companies demonstrated complex coordinated movements and dexterous hand operations, further highlighting the value of this technical direction.

D‑Robotics, originating from the AIoT and robotics division of Horizon Robotics, focuses on edge‑side embodied intelligence solutions characterized by high computing power, integrated computation and control, and low latency. Leveraging its parent company’s long‑term experience in intelligent driving, D‑Robotics has established a precise position in humanoid robot “Brain-Cerebellum” coordination and real‑time joint control.

In November 2025, D‑Robotics unveiled its flagship robotics computing platform S600, with an official release planned for the end of the first quarter of 2026. The S600 platform features a highly integrated humanoid‑style “Brain-Cerebellum” chipset architecture. Its “Brain” configuration combines an 18‑core A78AE CPU with a proprietary Nash‑architecture BPU, delivering 560 TOPS (INT8) edge computing power and supporting efficient deployment of VLA, VLM, LLM, and locomotion models. Its “Cerebellum” configuration integrates a 6‑core R52+ MCU, providing high‑reliability, real‑time motion control.

By integrating CPU, BPU, and real‑time MCU capabilities into a single SoC, S600 enables a closed‑loop architecture encompassing perception, decision‑making, and real‑time action control. This design addresses a key industry challenge in which many edge AI processors lack embedded real‑time MCUs and rely on external controllers, resulting in excessive latency. The integrated MCU supports high‑frequency, high‑precision PWM signal generation based on FOC algorithms, enabling precise motor control and contributing to stable rhythm and natural gait.

The S600 platform has been adopted by multiple robotics companies such as Fourier Intelligence, Booster Robotics, X Square Robot, and ROBOTERA, supporting applications that require stable multi‑joint coordination and smooth motion performance.

Ingdan, Inc. (00400.HK) is a core supplier in the AI computing power supply chain and an application technology solutions provider covering both AI infrastructure and AI intelligent terminals. The Company represents a broad portfolio of international semiconductor manufacturers, including NVIDIA, Xilinx, Intel, AMD, and SanDisk, as well as numerous domestic chip vendors. It serves hundreds of robotics manufacturers and Tier‑1 customers and has formed a comprehensive embodied intelligence ecosystem.

D‑Robotics is a core product line Ingdan distributes . Building on D‑Robotics’ products and combined with its own technical services—such as multi‑sensor fusion development, real‑time closed‑loop tuning, Quantization‑Aware Training (QAT) support, simulation testing, and modular SOM customization—the Group has supported sophisticated customers including Galbot and ROBOTERA, continuously enriching the robotics industry ecosystem.

Looking ahead, Ingdan will continue to focus on the humanoid robotics sector. Leveraging an IC product matrix centered on NVIDIA Jetson and D‑Robotics platforms, the Company aims to further strengthen its AI intelligent terminal capabilities and continue supporting the iterative development of embodied intelligence products.

For investor and media enquiries
Please email to **@****an.com

Hashtag: #Ingdan #Chips #humanoid #D‑Robotics #NVIDIA #Tech

The issuer is solely responsible for the content of this announcement.

Ingdan, Inc.

Ingdan, Inc. (00400.HK) is a core supplier in the AI computing power supply chain and an application technology solutions provider covering both AI infrastructure and AI intelligent terminals. The Company represents a broad portfolio of international semiconductor manufacturers, including NVIDIA, Xilinx, Intel, AMD, and SanDisk, as well as numerous domestic chip vendors. It serves hundreds of robotics manufacturers and Tier‑1 customers and has formed a comprehensive embodied intelligence ecosystem.

Continue Reading

Media OutReach

Snow, Ice, and Performance: 2026 Changan Global Testing Season Arrives in Europe with Back-to-Back Winter Events

Published

on

  • European dealers and journalists experienced the CHANGAN DEEPAL S05 AWD at 2026 Changan Global Testing Season this February.
  • With intelligent AWD and advanced ADAS, the CHANGAN DEEPAL S05 AWD offered uncompromising safety and control on winter roads.

Saalfelden, Austria – Media OutReach Newswire – 12 March 2026 – Following extreme cold tests in Yakeshi, China, the 2026 Changan Global Testing Season made its European debut this February with the Changan Winter Experience in Courmayeur and the Winter Test Drives in Saalfelden. The all-electric CHANGAN DEEPAL S05 AWD was tested on snow and ice—familiar conditions for European drivers—offering dealers and journalists an immersive introduction to Changan’s electric mobility vision through dynamic drives.

Three-time Olympic gold medalist and Milano Cortina 2026 Ambassador Deborah Compagnoni joined the event in Courmayeur, testing the CHANGAN DEEPAL S05 AWD. Her career—defined by determination, control, and reliability—reflects Changan’s core values. “I felt that the principles of trajectory and speed in skiing apply to driving. With this model, you gain confidence on challenging terrain,” she said.

Snow-Validated Performance: The CHANGAN DEEPAL S05 AWD

Tested in Europe, the CHANGAN DEEPAL S05 AWD demonstrated controllable dynamics, reliable traction, and enhanced safety—highlighting its cutting-edge AWD and ADAS. The system adapts seamlessly: ECO/COMFORT modes prioritize RWD efficiency, while AWD will engage automatically when sensors detect slip, high torque demand, or extreme cold below -25°C. SPORT mode delivers permanent 50:50 torque for sharper response. SNOW mode maintains balanced torque with optimized slip control for confident driving on low-grip surfaces.

The intelligent AWD system delivers up to 320 kW power, 502 Nm torque, and 0–100 km/h acceleration in 5.5 seconds. It also improves hill climbing with a 40% gradient capability, ensures stability by actively balancing power to prevent skidding, and enables safer cornering at higher speeds through optimized grip and vehicle dynamics.

Changan Standard: Proven in the Alps, Bound for the World

Changan Standard is defined by a principle: forged in extremes, built for every day. From Yakeshi to the Alps, the test environments are selected to verify specific performance attributes—safety technologies, chassis response, all-wheel-drive calibration, and ADAS in low-grip scenarios. The objective of 2026 Global Testing Season is not to demonstrate extremes, but to confirm consistency: that the same level of safety, control, and stability demonstrated will be replicated in Mexico, Thailand, and Saudi Arabia.

Hashtag: #Changan

The issuer is solely responsible for the content of this announcement.

Continue Reading

Trending